8-K: Wellgistics Settles $10.7M Liability, Expands Telehealth AI

Wellgistics Health secured court approval for a settlement agreement to resolve over $10.7 million in liabilities by issuing common stock and expanded its partnership with Tollo Health to integrate telehealth and mental health AI capabilities.

Summary

• A settlement agreement between Wellgistics Health, Inc. and Silverback Capital Corporation (SCC) was approved by the Circuit Court within the Twelfth Judicial Circuit of Florida on February 4, 2026.
• Under the agreement, SCC will settle bona fide liabilities and obligations of Wellgistics totaling not less than $10,712,734.16.
• Wellgistics will issue shares of its common stock to SCC to satisfy this claim amount, with the share price for tranches ranging from $0.25 to $2.25 per share.
• An amendment on February 9, 2026, fixed the price for the first $2,250,000 tranche at $0.25 per share.
• Additionally, Wellgistics will issue 100,000 shares as a settlement fee and 300,000 shares to cover legal fees and expenses related to the settlement.
• Wellgistics expanded its partnership with Tollo Health, LLC, to add telehealth services via TolloCare, LLC, a Tollo Health subsidiary.
• TolloCare will initially focus on GLP-1 and Long COVID patients, expanding to include mental health AI offerings through a partnership with a San Francisco Bay Area startup, and will service Wellgistics' emerging partnership with NFL Alumni Health.
• Gerald Commissiong was appointed as consulting Chief Business Officer on February 6, 2026, through a consulting agreement with Fortitude Advisors, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While resolving a significant liability is positive, the method of resolution (share issuance at low prices) and the underlying existence of such a large liability are concerning. The strategic expansion into telehealth and AI is a positive long-term move, but its immediate impact is offset by the financial implications of the settlement.

Positives

• Resolution of significant liabilities totaling over $10.7 million through a court-approved settlement agreement.
• Expansion into telehealth and mental health AI services through an expanded partnership with Tollo Health, positioning the company in growing healthcare segments.
• TolloCare's white-labeled telehealth capabilities include access to over 5,000 onboarded physicians nationwide.
• Strategic focus on high-demand areas like GLP-1 and Long COVID patients, and future expansion into mental health, weight loss, cardiometabolic disease, sleep apnea, and pain management.
• Appointment of Gerald Commissiong as consulting Chief Business Officer, potentially bringing new business development expertise.
• Forzet distribution is ready to begin this quarter.

Negatives

• The existence of over $10.7 million in bona fide liabilities requiring settlement indicates past financial challenges.
• Issuance of common stock to settle liabilities will result in dilution for existing shareholders.
• Additional issuance of 100,000 shares for a settlement fee and 300,000 shares for legal fees further contributes to dilution.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Unanticipated factors could arise that cause actual future results to differ from expectations.
• Risks regarding forward-looking statements are discussed in the company's SEC filings, including its Registration Statement on Form S-1 (effective September 25, 2025).
• The success of the new telehealth and AI initiatives depends on effective implementation and market acceptance.
• The issuance of shares at potentially low prices ($0.25 per share for the first tranche) could indicate a low valuation or significant dilution.

Future Outlook

The company anticipates evolving its business model from pharmaceutical distribution-only to more comprehensively service patients through its Wellgistics Pharmacy Network and online pharmacy. It expects to leverage Tollo Health's intellectual capital to educate healthcare professionals on GLP-1 agonist drugs and Forzet, with Forzet distribution ready to begin this quarter. TolloCare intends to expand its focus into mental health, weight loss (post-GLP-1), cardiometabolic disease, sleep apnea, and pain management.

Management Comments

• "As we evolve our business model from pharmaceutical distribution-only to more comprehensively service patients both through our Wellgistics Pharmacy Network and our own online pharmacy, we understand that we must meet the patients where they are and provide convenient solutions that improve their outcomes." Prashant Patel, RPh, President & Interim-CEO.
• "Given that Forzet distribution is ready to begin this quarter, we believe now is the right time to expand into telemedicine." Prashant Patel, RPh, President & Interim-CEO.
• "It makes sense for us to leverage their intellectual capital to help to educate physicians and pharmacists on how best to use GLP-1 agonist drugs together with Forzet." Prashant Patel, RPh, President & Interim-CEO.

Industry Context

StockSavvy.ai notes that Wellgistics Health's expansion into telehealth and mental health AI aligns with broader industry trends of digital transformation in healthcare, increasing patient demand for convenient online services, and the growing focus on mental health and chronic disease management (like GLP-1 for weight loss and Long COVID). This move positions Wellgistics to capitalize on these high-growth segments, moving beyond its traditional pharmaceutical distribution model. The integration of AI platforms like EinsteinRx and blockchain-enabled PharmacyChain also reflects the industry's push towards optimizing supply chains and patient access through advanced technology.

Comparison to Industry Standards

• StockSavvy.ai observes that the expansion into telehealth and AI-driven mental health services positions Wellgistics to compete with established telehealth providers like Teladoc Health (TDOC) and Amwell (AMWL), as well as emerging AI mental health platforms.
• The stated access to over 5,000 physicians nationwide for telehealth services is a significant scale, comparable to the network sizes of major telehealth players, indicating a robust operational foundation for its new TolloCare subsidiary.
• The focus on GLP-1 and Long COVID patients targets high-growth, specialized areas, similar to how companies like WeightWatchers (WW) are integrating GLP-1 support, or specialized clinics addressing post-viral syndromes.
• The integration of AI for pharmacy optimization (EinsteinRx) and blockchain for supply chain (PharmacyChain) aligns with innovative practices seen in pharmaceutical logistics and health tech, aiming for efficiency and transparency, similar to initiatives by larger pharmaceutical distributors or tech-focused healthcare startups.

Management Changes

Corporate Governance

Legal Proceedings

• The Circuit Court within the Twelfth Judicial Circuit of Florida approved a Settlement Agreement and Stipulation between Wellgistics Health, Inc. and Silverback Capital Corporation, resolving a legal dispute or claim related to significant liabilities.

Related Party Transactions

• A consulting agreement was entered into with Fortitude Advisors, LLC, an entity owned and controlled by Gerald Commissiong, who was appointed as consulting Chief Business Officer.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of common stock to settle liabilities and cover fees. The low share price for the first tranche ($0.25) could negatively impact per-share value.
• Creditors (Silverback Capital Corporation) will receive common stock in satisfaction of over $10.7 million in liabilities, converting debt/claims into equity.
• Employees: The appointment of a consulting Chief Business Officer and strategic expansion into new healthcare segments could lead to new opportunities or shifts in operational focus.
• Customers (Pharmacies, Patients): The expansion into telehealth, mental health AI, and direct-to-patient services through TolloCare aims to provide more convenient solutions and improve patient outcomes, potentially expanding the customer base.
• Suppliers (Manufacturers): The company's integrated platform connects with over 200 manufacturers, and the strategic shift could influence future partnerships or distribution channels.

Next Steps

• Issuance of common stock to Silverback Capital Corporation in one or more tranches to satisfy the $10,712,734.16 claim amount.
• Distribution of Forzet is expected to begin this quarter.
• TolloCare intends to expand its focus into mental health, weight loss (post-GLP-1), cardiometabolic disease, sleep apnea, and pain management.
• Wellgistics will continue to evolve its business model to service patients through its Pharmacy Network and online pharmacy.

Key Dates

Recommendation

While the resolution of a significant liability is a positive step towards cleaning up the balance sheet, the substantial dilution from issuing shares at a low price is a concern for existing shareholders. The strategic pivot into telehealth and AI-driven mental health services through the Tollo Health partnership is promising and aligns with growth trends in healthcare, but these initiatives are still in early stages and their impact on future profitability is uncertain. The appointment of a new consulting Chief Business Officer could bring valuable expertise. Given the mixed signals—addressing past issues with dilutive measures while pursuing future growth—a "hold" recommendation is appropriate as investors await clearer signs of successful execution and financial improvement from the new strategic direction.

Keywords

telehealth, mental health AI, GLP-1, Long COVID, settlement agreement, equity issuance, pharmacy network, blockchain, AI platform, healthcare technology, WGRX, corporate governance